Dynavax(US:DVAX) Benzinga·2025-12-25 05:27Group 1: Acquisition Details - Sanofi will commence a cash tender offer to acquire all outstanding shares of Dynavax Technologies at $15.50 per share, representing approximately $2.2 billion in total equity value [2] - The offer price reflects a 39% premium over Dynavax's closing price on December 23 and a 46% premium over its three-month volume-weighted average price as of December 23 [2] - The Dynavax board has unanimously approved the transaction [4] Group 2: Product and Pipeline - The acquisition includes HEPLISAV-B, an adult hepatitis B vaccine available in the U.S., which is administered in two doses over one month, unlike the traditional three-dose schedule [3] - Sanofi's Executive Vice President of vaccines stated that Dynavax enhances Sanofi's adult immunization presence by adding differentiated vaccines [3] Group 3: Regulatory and Financial Aspects - The acquisition is subject to regulatory approvals, including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act, and other customary conditions [5] - Sanofi intends to fund the acquisition with available cash [6] - Dynavax was advised by Centerview Partners LLC and Goldman Sachs & Co. LLC during the transaction [6] Group 4: Stock Performance - Shares of Dynavax surged 38.19% in regular trading on Wednesday, closing at $15.38, before slightly tapering to $15.37 in after-hours trading [1] - The stock has a market capitalization of $1.81 billion and has gained 18.04% over the past 12 months and 55.98% over the last six months [7] - Currently, the stock is trading at 98.3% of its 52-week range, indicating it is near its highs, which reinforces bullish sentiment [8]